UBS’s $15 target on KURA

KURA Kura Oncology Inc

$10.7 → $15 (+41%) by Oct 2027

Buy · reiterates · said Oct 5, 2026 · 12-month default horizon

Open: judged on the close on Oct 5, 2027

The article this target came from

UBS reiterates Kura Oncology stock rating on strong launch metrics

Investing.com · Oct 5, 2026

Investing.com - UBS reiterated a Buy rating and $15.00 price target on Kura Oncology (NASDAQ:KURA) shares, representing roughly 41% upside from the current price of $10.65.

UBS’s track record → Kura Oncology Inc →

A fact about what UBS published, as reported by Investing.com, not a recommendation from Dalsna Finance; UBS is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.